João Conde is an Assistant Professor and Group Leader at NOVA Medical School of Universidade Nova de Lisboa, ToxOmics, CEDOC. He received his PhD in Biology, specialty in NanoBiotechnology from the NOVA University and Universidad de Zaragoza in 2014, under the FP7 European Consortium NanoScieE+ – NANOTRUCK for the development of multifunctional gold nanoparticles for gene silencing. After, he was a Marie Curie Fellow at the Massachusetts Institute of Technology, Harvard-MIT Division for Health Sciences and Technology and in School of Engineering and Materials Science, Queen Mary University of London. From 2017 to 2019 he was a Junior Investigator at Instituto de Medicina Molecular. In 2019, he won an ERC Starting Grant to build a genetic biobarcode to profile breast cancer heterogeneity. He is also co-founder of the biotech company TargTex, Targeted Therapeutics for Glioblastoma Multiforme.

The main aspects related to the recognition and diffusion of his early contributions are: nearly 70 articles in journals of Cancer therapy, Materials Science and Biomedicine (Nat. Materials, Nat. Nanotechnology, Nat. Communications, PNAS, Accounts of Chemical Research, Progress in Materials Science, ACS Nano, Advanced Materials, JACS, Angewandte Chemie, Advanced Functional Materials, Trends in Cancer, Trends in Biotech., Biomaterials, etc.), more than 30 articles are as 1st author and more than 20 articles as corresponding author and cited more than 4300 times (h-index 36). Eight of them have been selected as cover page of journals such as Adv. Functional Materials, JACS, Angewandte Chemie, Adv. Healthcare Materials, Analytical & Bioanalytical Chemistry and BioTechniques. Moreover, 6 international patents were submitted and approved, all with relevant developments in nanomaterials-based platforms for cancer therapy and diagnosis. He was also awarded with several international awards, including the Wellcome Image Awards 2017, the Nano-Micro Letters Researcher Award, and the National Cancer Institute Image award.

Conde Lab is focused on the application of multifunctional nano-and-biomaterials for cancer therapy and diagnosis, especially for tumour imaging and targeting, gene therapy/editing and drug delivery.